Rubella reimmunization: Comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals

Journal of Clinical Microbiology

Volumn 34, Issue 9, 1996, Pages 2210-2218

  Mitchell, Leslie Ann ^a,g   Ho, Margaret K L ^a   Rogers, Janet E ^a   Tingle, Aubrey J ^a   Marusyk, Raymond G ^b   Weber, John M ^c   Duclos, Philippe ^d   Tepper, Martin L ^e   Lacroix, Martial ^f   Zrein, Maan ^f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

^c Bureau of Microbiology   (Canada)

^d LAB CENTRE FOR DISEASE CONTROL   (Canada)

^e DEPARTMENT OF NATIONAL DEFENCE   (Canada)

^f INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RUBELLA VACCINE;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; IMMUNIZATION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RUBELLA VIRUS; SEROCONVERSION; VACCINATION;

RUBELLA VIRUS;

EID: 9444231150     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.34.9.2210-2218.1996     Document Type: Article

References (48)

1. ACIP. 1990. Rubella prevention: ACIP recommendations. Morbid. Mortal. Weekly Rep. 39:1-18.
2. Assaad, F., and K. Ljungars-Esteves. 1985. Rubella - world Impact. Rev. Infect. Dis. 7(Suppl. 1):S29-S31.
3. Balfour, H. H., K. E. Groth, and C. K. Edelman. 1981. Rubella viremia and antibody responses after rubella vaccination and reimmunization. Lancet 1:1078-1080.
4. Banatvala, J. E., J. M. Best, S. O'Shea, and J. A. Dudgeon. 1985. Persistence of rubella antibodies after vaccination: detection after experimental challenge. Rev. Infect. Dis. 7(Suppl. 1):S85-S90.
5. Best, J. M. 1991. Rubella vaccines: past, present and future. Epidemiol. Infect. 107:17-30.
6. Burgess, M. A. 1992. Rubella reinfection - what risk to the fetus? Med. J. Aust. 156:824-825.
7. Centers for Disease Control. 1990. Increase in rubella and congenital rubella. Morbid. Mortal. Weekly Rep. 40:93-99.
8. Chaye, H., P. Chong, B. Tripet, B. Brush, and S. Gillam. 1992. Localization of the virus neutralizing and hemagglutinin epitopes of E1 glycoprotein of rubella virus. Virology 189:483-492.
9. Chernesky, M. A., F. Smaill, J. B. Mahony, and S. Castriciano. 1987. Combined testing for antibodies to rubella non-structural and envelope protein sentinel infections in two outbreaks. Diagn. Microbiol. Infect. Dis. 8:173-177.
10. Cusi, M. G., G. M. Rossolini, P. E. Valensin, C. Cellesi, and A. Zanchi. 1990. Serological evidence of reinfection among vaccinees during rubella outbreak. Lancet 336:1071.
11. Daffos, F., R. Forestier, L. Grangeot-Keros, M. Capella Pavlovsky, P. Lebon, M. Chartier, and J. Pillot. 1984. Prenatal diagnosis of congenital rubella. Lancet 8993:1.
12. Duclos, P., M. L. Tepper, J. Weber, and R. Marusyk. 1991. Seroprevalence of measles and rubella-specific antibodies among military recruits, Canada, 1991. Can. J. Public Health 85:278-281.
13. Edson, S. E., A. Lovett, E. Sukholutsky, and J. S. Wolinsky. 1993. A synthetic chimeric peptide rapidly induces rubella-specific neutralizing antibodies, abstr. 48.5, p. A111. In Abstracts of the American Society for Virology Annual Meeting. American Society for Virology.
14. Eisele, C. J. 1993. Rubella susceptibility in women of childbearing age. J. Obstet. Gynecol. Neonatal Nurs. 22:260-263.
15. Enders, G., U. Nickerl-Pacher, and E. Miller. 1988. Outcome of confirmed periconceptional maternal rubella. Lancet 1:1445-1447.
16. Fogel, A., C. B. Gerichter, B. Barnea, R. Handsher, and E. Heeger. 1978. Response to experimental challenge in persons immunized with different rubella vaccines. J. Pediatr. 92:26-30.
17. Forsgren, M., and L. Soren. 1985. Subclinical rubella reinfection in vaccinated women with rubella-specific IgM response during pregnancy and transmission of virus to the fetus. Scand. J. Infect. Dis. 17:337-341.
18. Frey, T. K. 1994. Molecular biology of rubella virus. Adv. Virus Res. 44:69-160.
19. Grillner, L. 1971. Neutralizing antibodies after rubella vaccination of newly delivered women: a comparison between three vaccines. Scand. J. Infect. Dis. 7:169-172.
20. Marcus, A. W., A. E. Ward, and K. A. Bryett. 1986. Rubella vaccination: a study in adult male volunteers. Curr. Med. Res. Opin. 10:291-295.
21. Herrmann, K. L. 1991. Rubella in the United States: toward a strategy for disease control and elimination. Epidemiol. Infect. 107:55-61.
22. Hillary, I. B., and A. H. Griffith. 1984. Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine. Vaccine 2:274-276.
23. Hornstein, L., U. Levy, and A. Fogel. 1988. Clinical rubella with virus transmission to the fetus in a pregnant woman considered to be immune. N. Engl. J. Med. 319:1415-1416.
24. Keith, C. G. 1991. Congenital rubella infection from reinfection of previously immunised mothers. Aust. N. Z. J. Ophthalmol. 19:291-293.
25. Kiefer, D. J. (Diamedix Corporation). Personal communication.
26. Miller, E., J. E. Cradock-Watson, and T. M. Pollock. 1982. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 8032: 781-782.
27. Miller, K. A., and T. D. Zagar. 1984. Rubella susceptibility in an adolescent female population. Mayo Clin. Proc. 59:31-34.
28. Mitchell, L. A., et al. Unpublished data.
29. Mitchell, L. A., D. Decarie, R. Shukin, A. J. Tingle, D. K. Ford, M. Zrein, and M. Lacroix. 1994. Case report: observation in chronic rubella-associated arthritis of cellular hyperimmunoreactivity to rubella virus synthetic peptides. Ann. Rheum. Dis. 52:590-594.
30. Mitchell, L. A., A. J. Tingle, R. Shukin, J. A. Sangeorzan, J. McCune, and D. K. Braun. 1994. Rubella vaccine-associated chronic musculoskeletal syndrome. Arch. Intern. Med. 153:2268-2274.
31. Mitchell, L. A., T. Zhang, M. Ho, D. Decarie, A. J. Tingle, M. Zrein, and M. Lacroix. 1992. Characterization of rubella virus-specific antibody responses by using a new synthetic peptide-based enzyme-linked immunosorbent assay. J. Clin. Microbiol. 30:1841-1847.
32. Morgan-Capner, P., E. Miller, J. E. Vardien, and M. E. B. Ramsay. 1991. Outcome of pregnancy after maternal reinfection with rubella. Commun. Dis. Rep. 1:R57.
33. Naficy, K., N. Rakhshandeh, S. Ahangary, and H. Mohsenin. 1970. Artificial challenge studies in rubella. Utilization of RA27/3 rubella vaccinees, rubella naturally acquired seropositives, and rubella susceptible children. Am. J. Dis. Child. 120:520-523.
34. National Committee for Clinical Laboratory Standards. 1992. Evaluation and performance criteria for multiple component test products intended for the detection and quantitation of rubella IgG antibody. NCCLS document 1/LAB-T/, vol. 12, p. 1-3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
35. O'Shea, S., J. M. Best, and J. E. Banatvala. 1983. Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. J. Infect. Dis. 148:639-646.
36. O'Shea, S., G. Parsons, and J. M. Best. 1981. How well do low levels of rubella antibody protect? Lancet ii:1284.
37. Plotkin, S. A., J. D. Farquar, and P. L. Ogra. 1973. Immunologie properties of RA27/3 rubella virus vaccine. A comparison with strains presently licensed in the United States. JAMA 226:585-590.
38. Robinson, R. G., F. E. Dudenhoeffer, H. J. Holroyd, L. R. Baker, D. I. Bernstein, and J. D. Cherry. 1982. Rubella immunity in older children, teenagers, and young adults: a comparison of immunity in those previously immunized with those unimmunized. J. Pediatr. 101:188-191.
39. Schiff, G. M., B. C. Young, and G. M. Stefanovic. 1985. Challenge with rubella virus after loss of detectable vaccine-induced antibody. Rev. Infect. Dis. 7(Suppl. 1):S157-S163.
40. Schluederberg, A., D. M. Horstmann, W. A. Andiman, and M. F. Randolph. 1978. Neutralizing and hemagglutination-inhibiting antibodies to rubella virus as indicators of protective immunity in vaccinees and naturally immune individuals. J. Infect. Dis. 138:877-883.
41. Stephen, C., A. Bell, and M. Johnson. 1994. Examining exanthemas: an accounting of British Columbia measles and rubella in 1993. B. C. Health Dis. Surv. 3:72-80.
42. Terry, G. M., L. Ho-Terry, P. Londesborough, and K. R. Rees. 1988. Localization of the rubella El epitopes. Arch. Virol. 98:189-197.
43. Tingle, A. J., J. K. Chantler, K. H. Pol, D. W. Paty, and D. K. Ford. 1985. Postpartum rubella immunization. Association with the development of prolonged arthritis, neurological sequelae, and chronic rubella viremia. J. Infect. Dis. 152:606-612.
44. Wolinsky, J. S. 1990. Rubella, p. 815-838. In B. N. Fields and G. M. Knipe (ed.), Virology. Raven Press, New York.
45. Wolinsky, J. S., E. Sukholutsky, W. T. Moore, A. Lovett, M. McCarthy, and B. Adame. 1993. An antibody- and synthetic peptide-defined rubella virus E1 glycoprotein neutralization domain. J. Virol. 67:961-968.
46. World Health Organization. 1971. WHO expert committee on biological standardization, 23rd report, p. 18. Technical Report Series No. 463. World Health Organization, Geneva.
47. Zhang, T., C. A. Mauracher, L. A. Mitchell, and A. J. Tingle. 1992. Detection of rubella virus-specific immunoglobulin G (IgG), IgM, and IgA antibodies by immunoblot assays. J. Clin. Microbiol. 30:824-830.
48. Zrein, M., J. H. Joncas, L. Pedneault, L. Robillard, R. J. Dwyer, and M. Lacroix. 1993. Comparison of a whole-virus enzyme immunoassay (EIA) with a peptide-based EIA for detecting rubella virus immunoglobulin G antibodies following rubella vaccination. J. Clin. Microbiol. 31:1521-1524.